摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-methylaminomethyl-2-thio-uracil | 21263-85-4

中文名称
——
中文别名
——
英文名称
5-methylaminomethyl-2-thio-uracil
英文别名
5-methyl-aminomethyl-thiouracil;5-((Methylamino)methyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one;5-(methylaminomethyl)-2-sulfanylidene-1H-pyrimidin-4-one
5-methylaminomethyl-2-thio-uracil化学式
CAS
21263-85-4
化学式
C6H9N3OS
mdl
——
分子量
171.223
InChiKey
HFTVVHMKHFDYBV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    85.2
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    申请人:Alnylam Pharmaceuticals, Inc.
    公开号:US20160051691A1
    公开(公告)日:2016-02-25
    The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
    本发明提供了包含至少一个式(I)的亚单位的iRNA试剂: 其中: A和B分别独立于每次出现O、N(RN)或S; X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸基团、一个活化磷酸基团、一个活化亚磷酸基团、一个酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R; R是LG、-连接子-LG,或具有下面所示结构: LG独立于每次出现的是一种碳水化合物,例如,单糖双糖、三糖、四糖、寡糖多糖; RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基; Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
  • [EN] NUCLEIC ACID CHEMICAL MODIFICATIONS<br/>[FR] MODIFICATIONS CHIMIQUES D'ACIDE NUCLÉIQUE
    申请人:ALNYLAM PHARMACEUTICALS INC
    公开号:WO2010101951A1
    公开(公告)日:2010-09-10
    he present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    本发明提供了式(1)的核苷和包含至少一种式(2)核苷的寡核苷酸;发明的另一个方面涉及一种抑制细胞中基因表达的方法,该方法包括(a)将本发明的寡核苷酸与细胞接触;和(b)维持步骤(a)中的细胞足够长的时间以获得目标基因mRNA的降解。
  • [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS D'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
    申请人:MODERNATX INC
    公开号:WO2018170306A1
    公开(公告)日:2018-09-20
    The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    该披露涉及新型脂质和相关组合物。纳米粒子组合物包括一种新型脂质以及额外的脂质,如磷脂、结构脂质和PEG脂质。纳米粒子组合物还包括治疗和/或预防措施,如RNA,在将治疗和/或预防措施传递给哺乳动物细胞或器官方面非常有用,例如,调节多肽、蛋白质或基因表达。
  • [EN] siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS<br/>[FR] ARNSI POSSÉDANT AU MOINS DEUX LIGANDS À DEUX EXTRÉMITÉS DISTINCTES
    申请人:SILENCE THERAPEUTICS GMBH
    公开号:WO2019193189A1
    公开(公告)日:2019-10-10
    There is provided inter alia a conjugate for inhibiting expression of a target gene in a cell, said conjugate comprising a nucleic acid portion and ligand portions, said nucleic acid portion comprising at least one duplex region that comprises at least a portion of a first RNA strand and at least a portion of a second RNA strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene, said ligand portions comprising a linker moiety and a targeting ligand for in vivo targeting of cells and being conjugated exclusively to the 3' and/or 5' ends of one or both RNA strands, wherein the 5' end of the first RNA strand is not conjugated, wherein: (i) the second RNA strand is conjugated at the 5' end to the targeting ligand, and wherein (a) the second RNA strand is also conjugated at the 3' end to the targeting ligand and the 3' end of the first RNA strand is not conjugated; or (b) the first RNA strand is conjugated at the 3' end to the targeting ligand and the 3' end of the second RNA strand is not conjugated; or (c) both the second RNA strand and the first RNA strand are also conjugated at the 3' ends to the targeting ligand; or (ii) both the second RNA strand and the first RNA strand are conjugated at the 3' ends to the targeting ligand and the 5' end of the second RNA strand is not conjugated.
    提供了一种用于抑制细胞中靶基因表达的共轭物,该共轭物包括核酸部分和配体部分,所述核酸部分包括至少一个双链区域,该区域包括至少部分第一RNA链和至少部分第二RNA链,该第二RNA链至少部分与第一链互补,其中所述第一链至少部分与从所述靶基因转录的RNA的至少部分互补,所述配体部分包括连接子基团和用于体内细胞靶向的靶向配体,并且仅连接到一个或两个RNA链的3'和/或5'末端,其中第一RNA链的5'末端未连接,其中:(i) 第二RNA链在5'末端连接到靶向配体,其中(a) 第二RNA链还在3'末端连接到靶向配体,且第一RNA链的3'末端未连接;或(b) 第一RNA链在3'末端连接到靶向配体,且第二RNA链的3'末端未连接;或(c) 第二RNA链和第一RNA链的3'末端均连接到靶向配体;或(ii) 第二RNA链和第一RNA链的3'末端均连接到靶向配体,且第二RNA链的5'末端未连接。
  • [EN] PEGYLATED LIPIDS AND THEIR USE FOR DRUG DELIVERY<br/>[FR] LIPIDES PÉGYLÉS ET LEUR UTILISATION POUR UNE ADMINISTRATION DE MÉDICAMENT
    申请人:ALNYLAM PHARMACEUTICALS INC
    公开号:WO2012099755A1
    公开(公告)日:2012-07-26
    The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.
    这项发明提供了用于药物传递的聚乙二醇-脂质共轭物。
查看更多